Six Bard PowerPort Lawsuits Will Go Before Juries Between May 2026 and Feb. 2027

Six Bard PowerPort Lawsuits Will Go Before Juries Between May 2026 and Feb. 2027

The U.S. District Judge presiding over all federal Bard PowerPort lawsuits has released a new trial schedule for six bellwether trials, which will take place throughout 2026 and early 2027.

The Bard PowerPort port catheter is a totally implantable vascular access device (TIVAD) that is marketed to give physicians a safe and reliable way to deliver drugs directly into a patient’s bloodstream. It is typically used when repeated injections are expected, such as during chemotherapy. The system includes an injection port where the needle is inserted, which connects to a polyurethane catheter tube that carries medications into the body.

However, in recent years the PowerPort catheters have been linked to numerous implant failures, which thousands of port catheter lawsuits now claim are caused by barium sulfate degradation that compromises the strength of the device.

To date, more than 2,100 Bard PowerPort lawsuits have been filed against C.R. Bard, each raising allegations that the implant’s defective design led to catheter fractures and migration injuries.

Bard PowerPort Lawsuit Lawyers
Bard PowerPort Lawsuit Lawyers

Due to similar facts and law raised in the complaints, a Bard PowerPort multidistrict litigation was established in July 2023 in the District of Arizona under U.S. District Judge David G. Campbell to streamline discovery and pretrial proceedings.

Judge Campbell has ordered the parties to prepare for a series of “bellwether” trials that will provide parties the opportunity to see how juries respond to evidence and testimony likely to be repeated throughout the litigation.

Earlier this year, the Court selected six claims that are eligible for the first bellwether trials, which have been undergoing final preparations.

In a case management order (PDF) issued on November 14, Judge Campbell laid out the schedule for the bellwether trials with the first trial scheduled for April 21, 2026, followed by trial dates on July 7, August 18, October 13, December 1, and February 2, 2027. The schedule sets the trials several weeks later than originally thought. The first trial, involving claims by Robert Cook of Minnesota, was originally scheduled to begin on March 2, 2026.

While the outcomes of these early bellwether trials will not have any binding impact on other claims pending in the MDL or state courts, they will be closely watched by lawyers involved in the litigation. The average jury awards are expected to have a major impact on future Bard PowerPort lawsuit settlement negotiations.

However, if the bellwether trials do not result in a global agreement to settle Bard PowerPort lawsuits, Judge Campbell may begin remanding hundreds of individual claims to various U.S. District Courts nationwide for separate trials in the future.

Written By: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.



0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

An increasing number of Ozempic and Mounjaro users are reporting sudden, irreversible vision loss from NAION side effects, prompting new lawsuits and a federal push to consolidate blindness claims into a dedicated multidistrict litigation.
Cartiva is urging federal judges to reject consolidation of toe-implant lawsuits, arguing that an MDL would interfere with individual claim resolutions that the company says are already being handled efficiently outside of court.
The first Covidien Symbotex mesh bellwether has been restored to the 2026 trial calendar, signaling renewed momentum in a litigation where more than 2,000 similar claims are still awaiting resolution.